REVENUE MEMORANDUM CIRCULAR NO. 156-2022 issued on December 27, 2022 publishes the November 23, 2022 letter from Food and Drug Administration (FDA) Director General Samuel A. Zacate endorsing updates to the “List of VAT-Exempt Medicines” under Republic Act No. 11534 (CREATE Act), which now includes certain medicines prescribed for hypertension, diabetes, high cholesterol, tuberculosis, mental illness and cancer.
            As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.